Comparative Pharmacology
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus KAFOCIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFPIRAMIDE SODIUM versus KAFOCIN.
CEFPIRAMIDE SODIUM vs KAFOCIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefpiramide sodium is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death.
KAFOCIN (cefepime/enmetazobactam) is a combination of a fourth-generation cephalosporin (cefepime) and a β-lactamase inhibitor (enmetazobactam). Enmetazobactam inhibits extended-spectrum β-lactamases (ESBLs) and other class A β-lactamases, restoring cefepime's activity against β-lactamase-producing bacteria. Cefepime inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
1-2 g IV every 12 hours; maximum 8 g/day
1 g IV every 8 hours.
None Documented
None Documented
4-5 hours in normal renal function; prolonged to 12-20 hours in severe renal impairment (CrCl < 20 mL/min)
Terminal elimination half-life: 4.5-6.5 hours (increased to 12-18 hours in severe renal impairment; CrCl <30 mL/min).
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: 10-20%
Renal: 60-80% unchanged; biliary/fecal: 15-30% as metabolites; total clearance ~120 mL/min.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic